---
title: "BUZZ-Hims & Hers falls, set for tenth straight day of losses"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275793942.md"
description: "Shares of Hims & Hers Healthfell 4% to $16.01, marking the company's tenth consecutive day of losses. This decline follows the announcement of a $49 compounded version of Novo Nordisk’s Wegovy pill for weight loss, which was later withdrawn due to regulatory scrutiny. Additionally, HIMS faces a lawsuit from Novo for patent infringement related to semaglutide, the active ingredient in Wegovy. Year-to-date, HIMS shares have decreased by 50%."
datetime: "2026-02-12T18:19:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275793942.md)
  - [en](https://longbridge.com/en/news/275793942.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275793942.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275793942.md) | [繁體中文](https://longbridge.com/zh-HK/news/275793942.md)


# BUZZ-Hims & Hers falls, set for tenth straight day of losses

Shares of telehealth company Hims & Hers Health (HIMS.N) fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk’s Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator Co’s shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy

Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy “knockoffs” that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder

Up to last close, HIMS down 50% YTD

### Related Stocks

- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Stt Strt® SPDR® S&P®HlthCrSvcsETF (XHS.US)](https://longbridge.com/en/quote/XHS.US.md)
- [Defiance Leveraged Long +Income HIMS ETF (HIMY.US)](https://longbridge.com/en/quote/HIMY.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Hims & Hers Health, Inc. (HIMS.US)](https://longbridge.com/en/quote/HIMS.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Defiance Daily Target 2X Long HIMS ETF (HIMZ.US)](https://longbridge.com/en/quote/HIMZ.US.md)
- [iShares US Healthcare Providers ETF (IHF.US)](https://longbridge.com/en/quote/IHF.US.md)
- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports](https://longbridge.com/en/news/278185211.md)
- [Examining the Future: Nutex Health's Earnings Outlook](https://longbridge.com/en/news/277813656.md)
- [Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?](https://longbridge.com/en/news/278180989.md)
- [Novo Nordisk Finally Catches Bid After FDA Warns Telehealth Companies](https://longbridge.com/en/news/277805363.md)
- [ISS Recommends Against Re-Election of Novo Nordisk Chairman - BN](https://longbridge.com/en/news/277889191.md)